# US 2022/0034895 A1 · Method of Determining Disease State Risk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034895 A1
- Document ID: US20220034895A1
- Status: Published application
- Kind: A1
- Application number: 17/386,092
- Filed: 2021-07-27
- Published: 2022-02-03
- Earliest claimed: 2016-10-03
- Assignees: Lincoln Memorial University
- Applicants: Lincoln Memorial University
- Inventors: Paul L. Wood
- Web page: https://patentgrep.com/patent/US20220034895A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/57525: of the liver or pancreas
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/7028: Cancer
- G01N 2800/7085: Lipogenesis or lipolysis, e.g. fatty acid metabolism
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for determining colorectal cancer risk includes obtaining a blood sample of the subject, isolating serum or EDTA plasma from the blood sample, analyzing the serum or EDTA plasma to determine plasma levels of very long chain dicarboxylic acid (VLCDCA 28:4), comparing the determined plasmas level of VLCDCA 28:4 of the subject with a predetermined range of plasma levels of VLCDCA 28:4 of diagnosed subjects having colorectal cancer, and determining a colorectal cancer risk exists when the determined plasma level of VLCDCA 28:4 is within the predetermined range of plasma levels of VLCDCA.

## Claims

### Claim 1

A method of determining disease state risk in a subject for a disease state selected from the group consisting of kidney cancer, colorectal cancer, head and neck cancer, rheumatoid arthritis, and combinations thereof, the method comprising:
isolating serum or EDTA plasma from a blood sample;
determining a plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma;
comparing the determined plasma level of VLCDCA 28:4 from the isolated serum of EDTA plasma with a predetermined range of VLCDCA 28:4 plasma levels,
the predetermined range of VLCDCA 28:4 plasma levels previously
determined from multiple subjects not diagnosed as having the disease state; and
determining the disease state risk exists when the determined plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma is at least 25% lower than the predetermined range of VLCDCA 28:4 plasma levels.

### Claim 2 (depends on 1)

The method of claim 1, where the determined plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma is at least 50% lower than the predetermined range of VLCDCA 28:4 plasma levels.

### Claim 3 (depends on 1)

The method of claim 1, where the disease state is colorectal cancer and the determined plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma is at least 62% lower than the predetermined range of VLCDCA 28:4 plasma levels.

### Claim 4 (depends on 1)

The method of claim 1, where the disease state is colorectal cancer and the determined plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma is at least 68% lower than the predetermined range of VLCDCA 28:4 plasma levels.

### Claim 5 (depends on 1)

The method of claim 1, where the disease state is colorectal cancer and the determined plasma level of VLCDCA 28:4 from the isolated serum or EDTA plasma falls within a predetermined range of VLCDCA 28:4 plasma levels corresponding to a diagnosed active disease state.

### Claim 6 (depends on 1)

The method of claim 1, where the disease state risk is determined to exist, the method further comprising:
administering to the subject an amount of a very-long chain dicarboxylic acid sufficient to increase the plasma levels of VLCDCA 28:4 in the blood of the subject.

### Claim 7 (depends on 6)

The method of claim 6, where the very-long chain dicarboxylic acid includes a straight chain group including from 28 to 36 carbons and from 1 to 4 double bonds.

### Claim 8 (depends on 7)

The method of claim 7, where the very-long chain dicarboxylic acid is a compound having the formula:
HOOC—(CH2)4—CH═CH—CH2—CH═CH—CH2—CH═CH—CH2—CH═CH—(CH2)11—COOH.

### Claim 9 (depends on 6, 8)

The method of claim 6 7, where the very-long chain dicarboxylic acid is an ester of the very-long chain dicarboxylic acid of claim 8.

### Claim 10 (depends on 6)

The method of claim 6, where the very-long chain dicarboxylic acid is administered to the subject until an at least 8% increase in circulating VLDCA 28:4 is observed.

### Claim 11 (depends on 6)

The method of claim 6, where the very-long chain dicarboxylic acid is administered to the subject until an at least 15% increase in circulating VLDCA 28:4 is observed.

### Claim 12 (depends on 6)

The method of claim 6, where the blood sample is obtained through venipuncture.

### Claim 13

A method of validating the structure of a 28 to 36 carbon very-long chain dicarboxylic acid, the method comprising
isolating serum or EDTA plasma from a blood sample;
storing the serum or EDTA plasma in a low temperature environment;
mixing about 1 milliliter (mL) of methanol comprising 1 nanomole of [2H28] dicarboxylic acid 16:0 with the isolated serum or EDTA plasma;
mixing about 1 mL of distilled water and about 2 ml of tert-butyl methylether with the isolated serum or EDTA plasma;
separating an organic layer from the mixture;
drying the organic layer;
dissolving the dried organic layer in a combination of isopropanol, methanol, chloroform, and ammonium acetate;
performing mass spectrometry on the dissolved organic layer; and
quantifying anions of dicarboxylic acid using negative ion electrospray ionization to validate the dicarboxylic acid 28:4 structure

### Claim 14 (depends on 13)

The method of claim 13, where the combination of isopropanol, methanol, and chloroform is in a ratio of 4:2:1.

### Claim 15 (depends on 13)

The method of claim 13, where the ammonium acetate is present in the combination at an about 15 millimolar concentration.
